TP53 and cancer: Mutant p53 has been shown to upregulate the expression of the histone methyltransferases KMT2A (MLL1) and KMT2D (MLL2), which are alternative constituents of the histone H3K4 methyltransferase COMPASS complex, and the histone acetyltransferase KAT6A (MOZ), leading to a global increase in histone methylation and acetylation and cancer cell proliferation [100].